Report cover image

Global Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 196 Pages
SKU # APRC20106414

Description

Summary

According to APO Research, The global Dermatomycoses Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Dermatomycoses Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Dermatomycoses Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Dermatomycoses Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Dermatomycoses Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Dermatomycoses Drug include Vyome Biosciences Pvt Ltd, Viamet Pharmaceuticals Inc, TGV-Laboratories, Sol-Gel Technologies Ltd, Novan Inc, Helix BioMedix Inc, Dermala Inc, Daewoong Pharmaceutical Co Ltd and Blueberry Therapeutics Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Dermatomycoses Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Dermatomycoses Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Dermatomycoses Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dermatomycoses Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Dermatomycoses Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dermatomycoses Drug sales, projected growth trends, production technology, application and end-user industry.


Dermatomycoses Drug Segment by Company

Vyome Biosciences Pvt Ltd
Viamet Pharmaceuticals Inc
TGV-Laboratories
Sol-Gel Technologies Ltd
Novan Inc
Helix BioMedix Inc
Dermala Inc
Daewoong Pharmaceutical Co Ltd
Blueberry Therapeutics Ltd
Biolab Farmaceutica Ltda
Anacor Pharmaceuticals Inc

Dermatomycoses Drug Segment by Type

BB-2603
Dapaconazole
Clotrimazole
Others

Dermatomycoses Drug Segment by Application

Hospital
Clinic
Others

Dermatomycoses Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomycoses Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatomycoses Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomycoses Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatomycoses Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Dermatomycoses Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Dermatomycoses Drug Market Size Estimates and Forecasts (2020-2031)
1.4 Global Dermatomycoses Drug Sales Estimates and Forecasts (2020-2031)
1.5 Global Dermatomycoses Drug Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Dermatomycoses Drug Market Dynamics
2.1 Dermatomycoses Drug Industry Trends
2.2 Dermatomycoses Drug Industry Drivers
2.3 Dermatomycoses Drug Industry Opportunities and Challenges
2.4 Dermatomycoses Drug Industry Restraints
3 Dermatomycoses Drug Market by Manufacturers
3.1 Global Dermatomycoses Drug Revenue by Manufacturers (2020-2025)
3.2 Global Dermatomycoses Drug Sales by Manufacturers (2020-2025)
3.3 Global Dermatomycoses Drug Average Sales Price by Manufacturers (2020-2025)
3.4 Global Dermatomycoses Drug Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Dermatomycoses Drug Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Dermatomycoses Drug Manufacturers, Product Type & Application
3.7 Global Dermatomycoses Drug Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Dermatomycoses Drug Market CR5 and HHI
3.8.2 Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2024
3.8.3 2024 Dermatomycoses Drug Tier 1, Tier 2, and Tier 3
4 Dermatomycoses Drug Market by Type
4.1 Dermatomycoses Drug Type Introduction
4.1.1 BB-2603
4.1.2 Dapaconazole
4.1.3 Clotrimazole
4.1.4 Others
4.2 Global Dermatomycoses Drug Sales by Type
4.2.1 Global Dermatomycoses Drug Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Dermatomycoses Drug Sales by Type (2020-2031)
4.2.3 Global Dermatomycoses Drug Sales Market Share by Type (2020-2031)
4.3 Global Dermatomycoses Drug Revenue by Type
4.3.1 Global Dermatomycoses Drug Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Dermatomycoses Drug Revenue by Type (2020-2031)
4.3.3 Global Dermatomycoses Drug Revenue Market Share by Type (2020-2031)
5 Dermatomycoses Drug Market by Application
5.1 Dermatomycoses Drug Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Dermatomycoses Drug Sales by Application
5.2.1 Global Dermatomycoses Drug Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Dermatomycoses Drug Sales by Application (2020-2031)
5.2.3 Global Dermatomycoses Drug Sales Market Share by Application (2020-2031)
5.3 Global Dermatomycoses Drug Revenue by Application
5.3.1 Global Dermatomycoses Drug Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Dermatomycoses Drug Revenue by Application (2020-2031)
5.3.3 Global Dermatomycoses Drug Revenue Market Share by Application (2020-2031)
6 Global Dermatomycoses Drug Sales by Region
6.1 Global Dermatomycoses Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Dermatomycoses Drug Sales by Region (2020-2031)
6.2.1 Global Dermatomycoses Drug Sales by Region (2020-2025)
6.2.2 Global Dermatomycoses Drug Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Dermatomycoses Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Dermatomycoses Drug Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Dermatomycoses Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Dermatomycoses Drug Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Dermatomycoses Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Dermatomycoses Drug Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Dermatomycoses Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Dermatomycoses Drug Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Dermatomycoses Drug Revenue by Region
7.1 Global Dermatomycoses Drug Revenue by Region
7.1.1 Global Dermatomycoses Drug Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Dermatomycoses Drug Revenue by Region (2020-2025)
7.1.3 Global Dermatomycoses Drug Revenue by Region (2026-2031)
7.1.4 Global Dermatomycoses Drug Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Dermatomycoses Drug Revenue (2020-2031)
7.2.2 North America Dermatomycoses Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Dermatomycoses Drug Revenue (2020-2031)
7.3.2 Europe Dermatomycoses Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Dermatomycoses Drug Revenue (2020-2031)
7.4.2 Asia-Pacific Dermatomycoses Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Dermatomycoses Drug Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Dermatomycoses Drug Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Vyome Biosciences Pvt Ltd
8.1.1 Vyome Biosciences Pvt Ltd Comapny Information
8.1.2 Vyome Biosciences Pvt Ltd Business Overview
8.1.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
8.1.5 Vyome Biosciences Pvt Ltd Recent Developments
8.2 Viamet Pharmaceuticals Inc
8.2.1 Viamet Pharmaceuticals Inc Comapny Information
8.2.2 Viamet Pharmaceuticals Inc Business Overview
8.2.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
8.2.5 Viamet Pharmaceuticals Inc Recent Developments
8.3 TGV-Laboratories
8.3.1 TGV-Laboratories Comapny Information
8.3.2 TGV-Laboratories Business Overview
8.3.3 TGV-Laboratories Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
8.3.5 TGV-Laboratories Recent Developments
8.4 Sol-Gel Technologies Ltd
8.4.1 Sol-Gel Technologies Ltd Comapny Information
8.4.2 Sol-Gel Technologies Ltd Business Overview
8.4.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
8.4.5 Sol-Gel Technologies Ltd Recent Developments
8.5 Novan Inc
8.5.1 Novan Inc Comapny Information
8.5.2 Novan Inc Business Overview
8.5.3 Novan Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Novan Inc Dermatomycoses Drug Product Portfolio
8.5.5 Novan Inc Recent Developments
8.6 Helix BioMedix Inc
8.6.1 Helix BioMedix Inc Comapny Information
8.6.2 Helix BioMedix Inc Business Overview
8.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
8.6.5 Helix BioMedix Inc Recent Developments
8.7 Dermala Inc
8.7.1 Dermala Inc Comapny Information
8.7.2 Dermala Inc Business Overview
8.7.3 Dermala Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Dermala Inc Dermatomycoses Drug Product Portfolio
8.7.5 Dermala Inc Recent Developments
8.8 Daewoong Pharmaceutical Co Ltd
8.8.1 Daewoong Pharmaceutical Co Ltd Comapny Information
8.8.2 Daewoong Pharmaceutical Co Ltd Business Overview
8.8.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
8.8.5 Daewoong Pharmaceutical Co Ltd Recent Developments
8.9 Blueberry Therapeutics Ltd
8.9.1 Blueberry Therapeutics Ltd Comapny Information
8.9.2 Blueberry Therapeutics Ltd Business Overview
8.9.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
8.9.5 Blueberry Therapeutics Ltd Recent Developments
8.10 Biolab Farmaceutica Ltda
8.10.1 Biolab Farmaceutica Ltda Comapny Information
8.10.2 Biolab Farmaceutica Ltda Business Overview
8.10.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
8.10.5 Biolab Farmaceutica Ltda Recent Developments
8.11 Anacor Pharmaceuticals Inc
8.11.1 Anacor Pharmaceuticals Inc Comapny Information
8.11.2 Anacor Pharmaceuticals Inc Business Overview
8.11.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
8.11.5 Anacor Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Dermatomycoses Drug Value Chain Analysis
9.1.1 Dermatomycoses Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Dermatomycoses Drug Production Mode & Process
9.2 Dermatomycoses Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Dermatomycoses Drug Distributors
9.2.3 Dermatomycoses Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.